Myricetin reverses epithelial–endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1. (28th February 2022)

• Record Type: Journal Article
• Authors: Wang, Ming; Ren, Shanfa; Bi, Zhun; Zhang, Liang; Cui, Mengqi; Sun, Ronghao; Bao, Jiali; Gao, Dandi; Yang, Bo; Li, Xiaoping; Li, Mingjiang; Xiao, Ting; Zhou, Hong‐gang; Yang, Cheng
• Is Part Of: Phytotherapy research. Volume 36:Number 4(2022)
• Page Start: 1807
• Page End: 1821
• Publication Date: 2022-02-28
• Subjects: antitumor -- epithelial–endothelium transition -- hepatocellular carcinoma -- Myricetin -- PAR1 -- vasculogenic mimicry; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.7427
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract: Most antiangiogenic inhibitors targeting endothelium‐dependent vessels cannot inhibit tumor growth but promote tumor invasion and metastasis in some patients. Vasculogenic mimicry (VM) employs mechanisms that differ from those used to construct endothelium‐dependent vessels. Inhibiting VM may be a novel antiangiogenic strategy against alternative tumor vascularization. In this paper, myricetin was selected from among several flavonoid compounds as an effective PAR1 antagonist. In two different hepatocellular carcinoma (HCC) cell lines high‐expressed PAR1, myricetin inhibited cell migration, invasion and VM formation and reversed the expression of epithelial–endothelial transition (EET) markers by inhibiting PAR1 activation. Knockout of PAR1 inhibited HCC cell invasion and metastasis and weakened the inhibitory effect of myricetin on HCC cells. The migration, invasion and tube formation ability of PLC‐PRF‐5 cells were enhanced after PAR1 overexpression, and the inhibitory effect of myricetin was enhanced. A docking assay revealed that myricetin binds to Leu258 and Thr261 in the PAR1 activity pocket. Mutation of Leu258 and Thr261 inhibited the antitumor effect of myricetin in vitro and in vivo. In summary, myricetin reverses PAR1‐mediated EET and inhibits HCC cell invasion, metastasis, VM formation and angiogenesis by targeting PAR1, and Leu258 and Thr261 of PAR1 participate in VM and angiogenesis in HCC tissues.